GO:0030110 HLA-C specific inhibitory MHC class I receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030110 describes a molecular function in which a receptor binds an HLA-C class I MHC molecule and delivers an inhibitory signal to a lymphocyte.
• The best-characterized receptors carrying this activity are inhibitory killer-cell immunoglobulin-like receptors (KIRs), especially KIR2DL1, KIR2DL2 and KIR2DL3, which recognize HLA-C allotypes.
• HLA-C alleles are broadly divided into C1 and C2 groups according to the motif recognized by inhibitory KIRs, and this ligand-receptor pairing sets the threshold for NK-cell activation.
• HLA-C expression itself is controlled by an elaborate NK-specific regulatory system, so receptor activity must be interpreted together with ligand dosage.
• Altered HLA-C/KIR interactions have been linked to immune-related conditions including autism spectrum development, psoriasis and other immune disorders.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of HLA-C and KIR gene variants in NK and T cell systems.
Description
GO:0030110, HLA-C specific inhibitory MHC class I receptor activity, is a molecular function that combines recognition of an HLA-C class I MHC molecule with inhibitory signaling in a lymphocyte. It is a central element of NK-cell education and self-tolerance, because inhibitory receptors that engage self MHC class I ligands prevent unwanted lymphocyte activation. The function is not a generic MHC-binding activity: it is restricted to receptors that specifically engage the HLA-C subclass and transduce an inhibitory signal. The prototype receptors are members of the killer-cell immunoglobulin-like receptor (KIR) family, particularly KIR2DL1, KIR2DL2 and KIR2DL3, whose HLA-C specificity has been defined biochemically and structurally. Because HLA-C is highly polymorphic, the same receptor can be inhibitory for one allotype and not another, and this allelic discrimination is a major determinant of NK-cell responsiveness. The functional outcome of GO:0030110 therefore depends on both the receptor and the exact HLA-C ligand, making it a paradigm for allele-specific immune recognition. Researchers study this activity to understand NK-cell tolerance, antiviral and antitumor immunity, and the genetic architecture of immune-mediated disease.
HLA-C specific inhibitory MHC class I receptor activity At A Glance
| GO ID | GO:0030110 |
|---|---|
| GO term | HLA-C specific inhibitory MHC class I receptor activity |
| Ontology | molecular_function |
| Synonym | none listed in QuickGO |
| Major function | Binding an HLA-C class I MHC molecule to mediate inhibitory signaling in a lymphocyte |
| Prototype receptors | Inhibitory KIRs such as KIR2DL1, KIR2DL2 and KIR2DL3 |
| Ligand subclass | HLA-C class I MHC molecules, commonly grouped as C1 and C2 allotypes |
| Cellular context | Natural killer cells and other lymphocytes that express inhibitory MHC class I receptors |
| Research relevance | NK-cell education, self-tolerance, antiviral and antitumor immunity, and immune disease genetics |
What Is GO:0030110?
In this article, GO:0030110 is defined as the function of a lymphocyte receptor that binds a class I MHC molecule of the HLA-C subclass and, through that binding, delivers a signal that inhibits lymphocyte activation. The definition emphasizes three inseparable features: ligand identity (HLA-C), receptor identity (an inhibitory MHC class I receptor) and signaling consequence (inhibition of activation). It is therefore distinct from activating MHC class I recognition and from MHC class I binding that does not inhibit the lymphocyte.
Why Is HLA-C specific inhibitory MHC class I receptor activity Important in Cell Biology?
GO:0030110 matters because it defines the molecular basis of inhibitory self-recognition in lymphocytes, a process that prevents NK cells from attacking healthy HLA-C-expressing cells while still permitting responses against cells that lose MHC class I. Because HLA-C is extremely polymorphic and its expression is itself regulated by an NK-specific system, this single molecular function integrates ligand genetics, receptor genetics and cellular signaling into one decision point. Perturbations of HLA-C/KIR interactions have been associated with immune-related conditions such as autism spectrum development and psoriasis, and the same axis is central to antiviral and antitumor immunity. For researchers, GO:0030110 is therefore both a mechanistic target and a biomarker-relevant function that can be dissected with modern CRISPR models.
• It provides the molecular explanation for NK-cell self-tolerance toward HLA-C-expressing cells.
• It determines the activation threshold of NK cells through inhibitory KIR-HLA-C engagement.
• It explains why HLA-C allotype matching matters in transplantation and immune recognition.
• It links HLA-C expression levels to lymphocyte inhibition, because ligand dosage affects signaling.
• It is a model system for allele-specific receptor-ligand recognition in immunology.
• It is relevant to antiviral and antitumor immunity, where MHC class I loss releases inhibition.
• It has been studied in the context of neurodevelopmental and immune-mediated disease associations.
• It provides a functional readout for CRISPR screens and variant testing in NK cells.
• It helps interpret KIR gene-content and HLA-C genotype data in human cohorts.
• It is a target for engineering inhibitory receptor specificity in cell therapy research.
What Happens During HLA-C specific inhibitory MHC class I receptor activity?
Ligand recognition of HLA-C by an inhibitory receptor
In simple terms: An inhibitory receptor on a lymphocyte recognizes an HLA-C molecule on another cell.
The function begins when an inhibitory MHC class I receptor engages an HLA-C class I molecule. Inhibitory KIRs such as KIR2DL1, KIR2DL2 and KIR2DL3 are the prototype receptors for this activity, and their specificity for HLA-C has been established by functional and structural studies. HLA-C allotypes are commonly divided into C1 and C2 groups based on the motif that determines which inhibitory KIR they engage, so ligand recognition is allele-specific rather than generic. Structural analysis of an inhibitory KIR bound to an HLA-Cw3-related MHC class I molecule showed the molecular details of this interface.
Inhibitory signal transduction in the lymphocyte
In simple terms: Binding sends a stop signal into the lymphocyte so it does not become activated.
Ligand engagement by an inhibitory MHC class I receptor leads to signaling that inhibits activation of the lymphocyte, which is the defining consequence of GO:0030110. Inhibitory KIRs are the receptors through which this MHC class I-specific inhibition is delivered in human NK cells and T lymphocytes. The functional outcome is a raised threshold for lymphocyte activation, so that cells displaying adequate HLA-C are spared. This inhibitory signaling is distinct from activating MHC class I recognition, which can occur through other receptors such as KIR2DS4.
Integration with NK-cell education and tolerance
In simple terms: The inhibitory signal helps train NK cells to tolerate normal cells.
Inhibitory MHC class I receptors on human NK and T lymphocytes are central to self-tolerance and to the education of the NK-cell repertoire. Because HLA-C is a major self-ligand, engagement of HLA-C by inhibitory KIRs calibrates NK-cell responsiveness. The strength of this function depends on both receptor genotype and HLA-C allotype, which is why KIR/HLA-C combinations are analyzed together in functional studies. HLA-C expression is itself controlled by an elaborate NK-specific regulatory system, adding a further layer that shapes how much inhibitory ligand is available.
Allele-specific discrimination and receptor diversity
In simple terms: Different HLA-C variants are recognized differently by different receptors.
HLA class I allelic sequence and conformation regulate binding by leukocyte Ig-like receptors, illustrating that small sequence differences can change receptor engagement. For HLA-C-specific inhibitory KIRs, the C1 versus C2 grouping captures a major part of this allelic discrimination. Receptor diversity within the KIR family further expands the range of HLA-C recognition outcomes. This combinatorial diversity is why GO:0030110 is best studied as a receptor-ligand pair rather than as an isolated activity.
Consequences for lymphocyte activation and effector function
In simple terms: When the stop signal is strong, the lymphocyte stays quiet; when it is lost, activation can proceed.
The inhibitory signal delivered through HLA-C recognition restrains lymphocyte activation, which is the functional endpoint of GO:0030110. Loss or reduction of HLA-C on a target cell removes this restraint and can permit NK-cell activation, a principle that underlies MHC class I-dependent immune surveillance. Conversely, strong inhibitory input can limit responses against cells that retain HLA-C. Because the same receptor family includes activating members, careful discrimination between inhibitory and activating recognition is essential when interpreting experiments.
Key Genes Involved in GO:0030110 HLA-C specific inhibitory MHC class I receptor activity
The genes most directly tied to GO:0030110 encode HLA-C ligands and the inhibitory KIR receptors that recognize them, together with related MHC class I and NK receptor genes that shape the same functional axis.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-C | Class I MHC ligand of the HLA-C subclass recognized by inhibitory receptors | Central ligand for GO:0030110; allotype determines C1/C2 grouping |
| KIR2DL1 | Inhibitory KIR that recognizes HLA-C C2-group allotypes | Prototype receptor for HLA-C-specific inhibition |
| KIR2DL2 | Inhibitory KIR with HLA-C specificity | Receptor variant affecting NK-cell inhibition |
| KIR2DL3 | Inhibitory KIR structurally characterized with HLA-Cw3-related MHC class I | Structural model for HLA-C recognition |
| KIR2DS4 | Activating KIR that can recognize MHC class I independently of the classic inhibitory mode | Contrast for distinguishing inhibitory from activating recognition |
| KIR3DL1 | Inhibitory KIR family member recognizing MHC class I | Comparative receptor for MHC class I inhibition |
| KIR3DL2 | Inhibitory KIR family member | Context for KIR repertoire studies |
| KIR2DL4 | KIR family member studied in NK receptor biology | Receptor diversity reference |
| NKG2A | Inhibitory NK receptor recognizing MHC class I-related ligands | Comparative inhibitory receptor in lymphocytes |
| NKG2C | NK receptor associated with HLA-E in immune studies | Contrast for HLA-E versus HLA-C recognition |
| HLA-E | Class I MHC molecule studied with NKG2 receptors | Comparative MHC class I ligand |
| HLA-A | Class I MHC molecule recognized by other inhibitory receptors | Context for MHC class I receptor specificity |
| HLA-B | Class I MHC molecule recognized by other inhibitory receptors | Context for MHC class I receptor specificity |
| LILRB1 | Leukocyte Ig-like receptor whose binding is regulated by HLA class I sequence and conformation | Alternative inhibitory MHC class I receptor |
| LILRB2 | Leukocyte Ig-like receptor in the same family | Comparative HLA class I binding |
| B2M | Beta-2-microglobulin, obligate component of class I MHC molecules | Required for HLA-C surface expression and function |
| TAP1 | Peptide transporter supporting class I MHC presentation | Upstream pathway for HLA-C ligand display |
How Is HLA-C specific inhibitory MHC class I receptor activity Regulated?
The activity described by GO:0030110 is regulated at several levels. First, ligand availability is controlled by HLA-C expression, which is governed by an elaborate NK-specific regulatory system. Second, receptor engagement depends on HLA-C allelic sequence and conformation, which determine whether a given inhibitory receptor binds. Third, the inhibitory outcome is balanced against activating receptor inputs, so the net signal reflects the integration of inhibitory and activating recognition. Finally, the receptor repertoire itself is shaped during NK-cell education, so the functional strength of HLA-C-specific inhibition varies between individuals and cell states.
HLA-C specific inhibitory MHC class I receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-C | Immune recognition and allorecognition | Knock-in of C1 versus C2 allotypes in NK-cell lines |
| KIR2DL1 | NK-cell inhibition and immune regulation | Knockout and point-mutation in primary NK cells |
| KIR2DL3 | Structural model of HLA-C recognition | Recombinant receptor binding assays and knock-in reporters |
| KIR2DS4 | Activating versus inhibitory recognition | Overexpression and knockout comparison in lymphocyte lines |
| NKG2C / HLA-E | Psoriasis-associated NK receptor biology | Knockout models in immune cell lines for receptor-ligand studies |
Immune-mediated and inflammatory conditions
HLA-C and KIR genes that mediate GO:0030110 have been examined in immune-mediated conditions. NKG2C, HLA-E and their association with psoriasis illustrate how MHC class I-related NK receptor axes are studied in inflammatory skin disease. Because HLA-C is the ligand for inhibitory KIRs, variation in this receptor-ligand pair is a plausible contributor to immune dysregulation, although the precise mechanisms remain an active area of research.
Neurodevelopmental associations
Paternal HLA-C and maternal killer-cell immunoglobulin-like receptor genotypes have been studied in the development of autism, linking the HLA-C/KIR axis to a neurodevelopmental outcome. This work illustrates that GO:0030110-related genes can be investigated in non-classical immune contexts, while the underlying biology remains incompletely understood.
Antiviral and antitumor immunity
Inhibitory MHC class I recognition sets the threshold for NK-cell activation, which is directly relevant to antiviral and antitumor responses. When target cells lose HLA-C, the inhibitory signal mediated by GO:0030110 is reduced, which can permit lymphocyte activation. This principle is a foundation for understanding immune surveillance and for designing strategies that exploit MHC class I loss.
Transplantation and allorecognition
Because HLA-C allotypes differ in their recognition by inhibitory KIRs, the function described by GO:0030110 contributes to allorecognition and donor-recipient matching considerations. Structural and functional definition of KIR-HLA-C interfaces provides a basis for interpreting such differences.
From HLA-C specific inhibitory MHC class I receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of an inhibitory KIR change lymphocyte inhibition by HLA-C? | KIR knockout in NK-cell lines or primary NK cells |
| Which HLA-C residues determine receptor specificity? | HLA-C point-mutation and knock-in of C1/C2 motifs |
| Does HLA-C expression level set the inhibitory threshold? | HLA-C overexpression and promoter-variant knock-in |
| Can an activating receptor be converted to inhibitory specificity? | Receptor knock-in and domain-swap point mutations |
| How does allelic conformation affect receptor binding? | HLA class I point-mutation panels with binding assays |
| Which genes modify HLA-C-specific inhibition genome-wide? | CRISPR library screening in NK-cell models |
How to Study the HLA-C specific inhibitory MHC class I receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Recombinant binding assay | Direct receptor-ligand interaction | Defining HLA-C allotype specificity of inhibitory KIRs |
| Crystal structure analysis | Molecular interface of receptor and MHC class I | Explaining allele-specific recognition |
| NK cytotoxicity assay | Inhibition of lymphocyte activation | Testing functional consequence of HLA-C engagement |
| HLA-C expression quantification | Ligand dosage available for inhibition | Linking expression level to inhibitory strength |
| KIR/HLA-C genotyping | Receptor and ligand genotype combinations | Cohort association and functional stratification |
| CRISPR knockout | Loss-of-function effect of a receptor or ligand gene | Causal testing in NK or T cell models |
| CRISPR knock-in | Effect of a specific HLA-C or KIR allele | Allele-specific functional comparison |
| CRISPR library screen | Genome-wide modifiers of the inhibitory phenotype | Discovery of regulators of HLA-C-specific inhibition |
Receptor-ligand binding assays
Direct binding assays using recombinant inhibitory KIR ectodomains and HLA-C molecules define the specificity and affinity of the interaction that underlies GO:0030110. Structural studies of an inhibitory KIR bound to an HLA-Cw3-related MHC class I molecule provide a template for interpreting such data. Allelic panels are essential because HLA class I sequence and conformation regulate receptor binding.
NK-cell functional assays
Cytotoxicity and activation assays in NK cells measure the functional consequence of HLA-C-specific inhibitory receptor engagement. Comparing target cells that retain or lose HLA-C reveals how the inhibitory signal sets the activation threshold. These assays are the standard readout for the inhibitory outcome defined by GO:0030110.
Genotyping and expression analysis
KIR and HLA-C genotyping, together with HLA-C expression measurement, is used to relate receptor-ligand combinations to function. The NK-specific regulatory system controlling HLA-C expression makes expression analysis particularly informative. Cohort studies of KIR/HLA-C genotypes have been used to examine disease associations.
CRISPR perturbation and screening
CRISPR knockout, point mutation, knock-in and overexpression allow causal testing of genes in the HLA-C/KIR axis. Library screening can identify modifiers of HLA-C-specific inhibition in lymphocyte models. These approaches complement binding and functional assays by establishing direction of effect.
How CRISPR Can Be Used to Study GO:0030110 HLA-C specific inhibitory MHC class I receptor activity
Knockout
Knockout of an inhibitory KIR or of HLA-C removes one side of the receptor-ligand pair and tests whether the inhibitory function is required for lymphocyte restraint. Knockout of B2M or antigen-processing genes can be used to eliminate surface class I MHC and thereby abolish the ligand for GO:0030110. These models are useful for establishing causality in NK-cell functional assays.
Point Mutation
Point mutation of HLA-C residues that define C1 and C2 motifs allows precise testing of which positions control inhibitory receptor engagement. Point mutation of receptor residues at the KIR-HLA-C interface can convert or weaken specificity, guided by structural data. Because HLA class I sequence and conformation regulate receptor binding, point mutants are essential controls.
Knock-in
Knock-in of a specific HLA-C allotype or KIR allele into a defined cellular background creates an isogenic system for comparing inhibitory strength. This is particularly valuable because HLA-C expression is controlled by an NK-specific regulatory system that can be preserved or modified in the knock-in design. Knock-in models also permit testing of receptor variants identified in human cohorts.
Overexpression
Overexpression of HLA-C increases ligand density and can strengthen the inhibitory signal, while overexpression of an inhibitory KIR increases receptor availability. Overexpression is also used to study activating receptors such as KIR2DS4 in parallel, to contrast activating and inhibitory recognition. These models help define the dynamic range of GO:0030110 in lymphocytes.
How EDITGENE Supports HLA-C specific inhibitory MHC class I receptor activity Research
Researchers studying HLA-C specific inhibitory MHC class I receptor activity-related genes often need to determine whether a candidate gene is causally involved in lymphocyte inhibition or is merely correlated with it. Establishing causality requires controlled perturbation of HLA-C, KIR and modifier genes in relevant cellular backgrounds, followed by functional readouts of inhibitory signaling.
Contact EDITGENE today to design your custom CRISPR model for HLA-C specific inhibitory MHC class I receptor activity research.
Frequently Asked Questions About HLA-C specific inhibitory MHC class I receptor activity
What is HLA-C specific inhibitory MHC class I receptor activity?
It is the molecular function defined by GO:0030110, in which a lymphocyte receptor binds an HLA-C class I MHC molecule and delivers an inhibitory signal that restrains lymphocyte activation.
What genes are involved in HLA-C specific inhibitory MHC class I receptor activity?
The core genes are HLA-C and inhibitory KIR genes such as KIR2DL1, KIR2DL2 and KIR2DL3, with related MHC class I and NK receptor genes shaping the same axis.
Which receptors recognize HLA-C?
Inhibitory killer-cell immunoglobulin-like receptors, especially KIR2DL1, KIR2DL2 and KIR2DL3, are the prototype HLA-C-specific inhibitory receptors.
What is the difference between C1 and C2 HLA-C groups?
HLA-C allotypes are grouped as C1 or C2 according to the motif that determines which inhibitory KIR they engage, making recognition allele-specific.
Why is HLA-C specific inhibition important for NK cells?
It provides inhibitory self-recognition that raises the activation threshold and helps NK cells tolerate normal HLA-C-expressing cells.
Is HLA-C expression regulated?
Yes, HLA-C expression is controlled by an elaborate NK-specific regulatory system, so ligand dosage influences the strength of inhibition.
How is HLA-C specific inhibitory receptor activity studied experimentally?
It is studied with recombinant binding assays, structural analysis, NK-cell functional assays, genotyping and CRISPR perturbation models.
Can CRISPR be used to study HLA-C and KIR genes?
Yes, knockout, point mutation, knock-in and overexpression approaches allow causal testing of HLA-C and KIR variants in lymphocyte models.
What diseases are linked to HLA-C and KIR genes?
This axis has been examined in immune-mediated conditions such as psoriasis and in neurodevelopmental associations such as autism spectrum development.
What is the difference between inhibitory and activating KIR recognition?
Inhibitory KIRs deliver a signal that restrains lymphocyte activation, whereas activating receptors such as KIR2DS4 can recognize MHC class I in a different functional mode.
Conclusion
GO:0030110 captures a precise and consequential molecular function: the recognition of HLA-C class I MHC molecules by inhibitory receptors that restrain lymphocyte activation. Its specificity depends on HLA-C allotype, receptor identity and ligand dosage, all of which are shaped by the genetics and regulation of the HLA-C/KIR axis. Because this function sits at the interface of self-tolerance, antiviral and antitumor immunity, and immune-mediated disease, it is a productive target for mechanistic and translational research. CRISPR-based knockout, point-mutation, knock-in, overexpression and screening models now make it feasible to test causal roles of individual HLA-C and KIR variants in defined cellular systems.
References
- 1. Katz G et al.. 2004. MHC class I-independent recognition of NK-activating receptor KIR2DS4.. J Immunol 173(3):1819-25 PMID: 15265913
- 2. Maenaka K et al.. 1999. Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I.. Structure 7(4):391-8 PMID: 10196125
- 3. Jones DC et al.. 2011. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding.. J Immunol 186(5):2990-7 PMID: 21270408
- 4. Li H et al.. 2018. Identification of an elaborate NK-specific system regulating HLA-C expression.. PLoS Genet 14(1):e1007163 PMID: 29329284
- 5. Moretta A et al.. 1997. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes.. Immunol Rev 155:105-17 PMID: 9059886
- 6. Long EO et al.. 1997. Killer cell inhibitory receptors: diversity, specificity, and function.. Immunol Rev 155:135-44 PMID: 9059889
- 7. Gamliel M et al.. 2016. Paternal HLA-C and Maternal Killer-Cell Immunoglobulin-Like Receptor Genotypes in the Development of Autism.. Front Pediatr 4:76 PMID: 27517034
- 8. Patel F et al.. 2013. NKG2C, HLA-E and their association with psoriasis.. Exp Dermatol 22(12):797-9 PMID: 24279916
